Somu Subramaniam
Co-Founder & Managing Partner @ New Science Ventures
New York, United States
Somu Subramaniam is a Series B investor at New Science Ventures in New York focused on Health Care and Biotechnology. Somu Subramaniam, is currently a Managing Partner and co-founder of New Science Ventures, a New York-based venture capital firm that invests in both early and late stage companies, using novel scientific approaches to address significant unmet needs and create order of magnitude improvements in performance. Somu Subramaniam serves on severalBoards of companies managed in New Science Venture’s portfolio, including Achronix Semiconductor Corporation, RF Arrays, Inc., Lightwire, Inc., Silicon Storage Technology, Inc., MagSil Corporation, BioVex Inc., Trellis BioScience, Inc., and BioScale, Inc. Prior to starting New Science Ventures in 2004,Somu Subramaniam was a Director at McKinsey & Co. and at various times led their Strategy Practice, Technology Practice and Healthcare Practice. While at McKinsey, he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries.He was also a member of McKinsey’s Investment Committee.Somu Subramaniam received his undergraduate degree (B.Tech) from the Indian Institute of Technology and his M.B.A. from Harvard Business School.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries Somu Subramaniam invests in
Stages Somu Subramaniam invests in
Countries Somu Subramaniam invests in
Investment Focus
Industry
- Health Care 4 (25%)
- Biotechnology 4 (25%)
- Manufacturing 4 (25%)
- Medical 2 (13%)
- Electronics 2 (13%)
Stage
- Series B 8 (50%)
- Funding Round 3 (19%)
- Series A 2 (13%)
- Series C 1 (6%)
- Convertible Note 1 (6%)
Country
- United States 9 (56%)
- United Kingdom 2 (13%)
- The Netherlands 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Glydways
|
Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs. | $101.3M / Venture - Series Unknown / Sep 29, 2025 | |
Pakal Technologies
|
Pakal Technologies is a developer of IGTO-based semiconductors intended to revolutionize the IGBT market. The company's semiconductors use IGTO, a silicon device, that is a drop-in replacement for IGBTs and provides a significant performance upgrade, providing clients with efficient, scalable, and compatible semiconductors. | $25M / Series B / Jan 29, 2025 | |
|
Glydways
|
Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs. | $56M / Series B / Oct 05, 2023 | |
Paragraf
|
Paragraf is the world’s leading graphene-based electronic device design, development and manufacturing company. Building on our proprietary process to grow graphene directly on standard semiconductor industry substrates, Paragraf has pioneered the delivery of two-dimensional technologies at scale. Paragraf’s high-quality graphene – integratablewith standard semiconductor tool process lines – has unlocked the incorporation of this remarkable material into both existing and new electronic devices and applications. Through our world-first dedicated graphene device foundry, Paragraf delivers high-performance, low-power technologies to multiple markets and offers two-dimensional-material foundry services to customers and partners, providing graphene in chips to their device requirements. | $60M / Series B / Mar 01, 2022 | |
NorthSea Therapeutics
|
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $80M / Series C / Dec 17, 2021 | |
BrightVolt
|
BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013. | $16M / Series B / Oct 06, 2021 | |
Phase Four
|
Phase Four is a provider of electric propulsion (EP) for small satellites.The company was founded in 2015 to accelerate the advancement of its core differentiator, the Radio Frequency Thruster (RFT). The hallmark of Phase Four’s RFT is simplicity. Because the RFT omits a hollow cathode and high voltage electronics, three key improvements arerealized: 1) a 10x materials cost savings versus legacy EP systems, 2) a significant decrease in the size of power electronics, and 3) propellant agnosticism. In a first for EP, the Phase Four RF thruster accomplishes this while achieving performance in the same thrust, specific impulse (Isp), and efficiency class as legacy plasma propulsion solutions. | $26M / Series B / Jun 11, 2021 | |
Escalier Biosciences
|
Escalier Biosciences BV is a privately held biopharmaceutical company developing novel small molecule therapeutics that target ROR?t for the treatment of psoriasis and other autoimmune disorders. Escalier's lead topical and oral drug candidates are currently in late stage preclinical studies. Escalier is registered in The Netherlands withoffices in Nijmegen, The Netherlands and Encinitas, California. | $19M / Series B / Mar 13, 2018 | |
TigerConnect
|
TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems.Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California. | $23M / Series B / Jan 27, 2014 | |
Resolve Therapeutics
|
Resolve Therapeutics is a private biotechnology company that is dedicated to the goal of improving the lives of patients suffering from lupus. They are focused on the advancement their exciting, novel biologic compound, RSLV-125 from preclinical research through a phase IIa clinical trial. The company is based on the pioneering discoveries made byDr. Keith Elkon and Dr. Jeff Ledbetter in their laboratories at the University of Washington School of Medicine. | $5.8M / Series B / Nov 01, 2012 | |
| See all 16 investments → | |||
Co-Investors
Easton Capital
5 deals together
Forbion Capital Partners
5 deals together
BioGeneration Ventures
3 deals together
ACS, Actividades de Construcción y Servicios
2 deals together
Khosla Ventures
2 deals together
About New Science Ventures
New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.
New Science Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Somu Subramaniam
Co-Founder & Managing Partner
|
|||
Andrew Abrams
Vice President
|
|||
Brenda Marex
CFO
|
|||
Jean-Pierre Bizet
Partner
|
|||
|
John Cecil
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Somu Subramaniam invest in?
Somu Subramaniam invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series B and Funding Round stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Somu Subramaniam last invest?
The most recent investment recorded for Somu Subramaniam closed in Sep 2025. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
